Sarepta Therapeutics (SRPT) Misses Q1 EPS by 457c
Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($5.86), $4.57 worse than the analyst estimate of ($1.29). Revenue for the quarter came in at $253.5 million versus the consensus estimate of $242.4 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.